

## Columbia Team visits PBHRF Clinic

PRESS  
RELEASE

Doctors  
from Columbia University visit PBHRF—  
(Prasanta  
Banerji Homoeopathic Research Foundation)—  
to  
study the Banerji Protocol of homeopathy treatment for paediatric  
cancer

Kolkata,  
November 3, 2007: The alarming increase in the number of children  
afflicted with cancer in recent years has become a subject of serious  
concern internationally.

The  
well-known Columbia University in the USA has initiated an  
Integrative Therapies Program for Children with Cancer in its  
Division of Pediatric Oncology. Dr Elena Ladas and Dr Kara  
Kelly along with their three colleagues from Columbia  
University spent the entire day at PBHRF, Kolkata meeting  
over thirty cancer patients (pediatric), observing individual cases  
and interacting with Dr Prasanta Banerji, Founder and Managing  
Trustee, Dr Pratip Banerji, Co-Founder and Dy. Managing  
Trustee and other senior senior doctors of PBHRF to get a first-hand  
perspective on the Banerji Protocol of homoeopathic treatment  
for cancer

Classical  
homoeopathy has no specific remedy for any disease by name, but it  
has specificity for each individual case of disease. This approach of  
treating patients, on the basis of symptoms only, is basically a must  
in long standing chronic diseases, and changes from patient to  
patient.

The  
Banerji Protocol is a new method of treatment. Specific medicines are  
prescribed for specific diseases. Diseases are diagnosed with the use  
of modern/state-of-the-art methods. This is done because modern  
diagnostic approaches incorporate and help in the selection of  
medicines so that specific medicines could be easily prescribed for  
specific diseases. This is not practised in classical homoeopathy.  
The  
concept of prescribing a specific homoeopathic medicine for a disease  
on the basis of symptoms was first perceived and practised by Late  
Dr. Pareshnath Banerji. With the passage of time and the availability  
of new diagnostic tools like Ultrasonography, MRIs, cancer markers  
and other advanced tests, Drs Prasanta and Pratip Banerji were able  
to further streamline the treatment protocols accurately. The  
efficiency of this streamlining is reflected by the encouraging  
results of the Banerji Protocol.

Dr  
Elena Ladas, MS, RD is the Director of the Integrative Therapies

Program, Columbia University, U.S.A. Dr Ladas serves as Complementary/Alternative Medicine Chair for the American Dietetics Association's Oncology Nutrition Dietetic Practice Group. She is also a member of the Children's Oncology Group Nutrition Task Force Steering Committee, the National Cancer Institute's PDQ Complementary and Alternative Medicine Editorial Board and Advisory Board, and of the Children's Oncology Group's steering committee for complementary/alternative medicine.

Dr

Kara Kelly, MD, is the Medical Director of the Integrative Therapies Program for Children with Cancer. She is a pediatric oncologist with clinical expertise in the treatment of children with leukemia, lymphoma and histiolytic disorders. She currently serves as chair of the committee for complementary/alternative medicine at the Children's Oncology Group, the largest research consortium of pediatric oncology centres in the United States and Canada. Dr Kelly is a member of the National Cancer Institute's PDQ Complementary and Alternative Medicine Editorial Board.